Malononitrilamides (MNAs) in combination with cyclosporine synergistically prevent acute and treat ongoing skin allograft rejection

International Journal of Immunotherapy

Volumn 13, Issue 1-2, 1997, Pages 9-16

  Schorlemmer, H U ^a,b   Ruuth, E ^b   Kurrle, R ^a  

^a Behringwerke AG   (Germany)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; 2 CYANO N (4 CYANOPHENYL) 3 CYCLOPROPYL 3 OXOPROPIONAMIDE; CARBOXYMETHYLCELLULOSE; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN; MALONONITRILE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; FLOW CYTOMETRY; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SKIN ALLOGRAFT; SKIN TRANSPLANTATION; SURVIVAL TIME;

EID: 0031399987     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Morris R E, Huang X., Cao W, Zheng B , Shorthouse R.A. Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury Transplant. Proc , 27, 445, 1995.
2. Schorlemmer H U , Schwab W, Ruuth E., Kurrle R. Acute skin graft rejection can be prevented and treated in rat models by malononitnlamides Transplant. Proc , 28, 3048, 1996.
3. Lin Y., Segers C., Waer M. Efficacy of the malononitnlamide X 920 715 as compared with leflunomide in cardiac allo- and xenotransplantation in rats Transplant. Proc., 28, 3036, 1996.
4. Schorlemmer H.U., Kurrle R. Control of mouse-to-rat skin xenograft rejection by malononitnlamides Transplant. Proc., 28, 3037, 1996
5. Williamson R.A., Yea C M , Robson P.A., et al. Dehydroorotate dehydrogenase is a high affinity binding protein for A771726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol Chem , 270, 22467, 1995.
6. Schorlemmer H U., Brendel S., Bartlett R.R. Malononitrilamides prevent the development of murine systemic lupus erythematosus-like diseases in BDF1 hybrid mice and MRL/lpr autoimmune mice Transplant. Proc., 28. 3040, 1996.
7. Schorlemmer H.U., Kurrle R., Bartlett R.R. Malononitrilamides inhibit the development of various marine graft-vs-host diseases. Transplant. Proc , 28, 3043, 1996.
8. Schorlemmer H.U., Bartlett R.R., Kurrle R. Analogues of leflunomide's primary metabolite, the malononitnlamides, prevent the development of graft-versus-host disease. Transplant. Proc , 29, 1298, 1997.
9. Kurrle R , Bartlett R R , Ruuth E., Lauffer L., Schorlemmer H.U. Malononitrilamides inhibit T- and B-cell responsiveness. Transplant Proc., 28, 3053, 1996.
10. Kurrle R., Ruuth E , Bartlett R R., Lauffer L., Schorlemmer H.U. Malononitrilamides inhibit T- and B-cell responsiveness in different species. Transplant. Proc., 29, 1302, 1997.
11. Schorlemmer H.U., Seiler F.R., Bartlett R.R Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative. Transplant. Proc., 25, 763, 1993.
12. Wasowska B., Baldwin W M , Sanfilippo F. IgG alloantibody response to donor-specific blood transfusion in differential rat strain combinations as a prediction of renal allograft survival Transplantation, 53, 175, 1992.
13. Williams J.W, Xiao F, Foster P, Clardy C , McChesney L., Sankary H , Chong A.S.F. Leflunomide in experimental transplantation. Transplantation, 57, 1223, 1994